Back
Y-mAbs Therapeutics Quote, Financials, Valuation and Earnings
Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!
Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)
Sell
29
YMAB
Y-mAbs Therapeutics
Last Price:
10.01
Seasonality Move:
12.09%
7 Day Trial
ALL ACCESS PASS
$
7
Better Than Oil Stocks
CLICK HERE TO FIND OUT MOREY-mAbs Therapeutics Price Quote
$10.01
Y-mAbs Therapeutics Key Stats
Sell
29
Y-mAbs Therapeutics (YMAB)
is a Sell
Day range:
$9.88 - $10.34
52-week range:
$6.09 - $20.90
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
5.35
P/B ratio:
4.98%
Volume:
167.6K
Avg. volume:
268.3K
1-year change:
50.3%
Market cap:
$460.4M
Revenue:
$84.8M
EPS:
$-0.54
How Much Does Y-mAbs Therapeutics Make?
-
How Much Are Y-mAbs Therapeutics's Sales Annually?
YMAB Revenues are $84.8M -
How Much Profit Does Y-mAbs Therapeutics's Make A Year?
YMAB net income is -$21.4M
Is Y-mAbs Therapeutics Growing As A Company?
-
What Is Y-mAbs Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.1% -
What Is Y-mAbs Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Y-mAbs Therapeutics Stock Price Performance
-
Did Y-mAbs Therapeutics Stock Go Up Last Month?
Y-mAbs Therapeutics share price went down by -32.68% last month -
Did YMAB's Share Price Rise Over The Last Year?
YMAB share price rose by 50.3% over the past 1 year
What Is Y-mAbs Therapeutics 52-Week High & Low?
-
What Is Y-mAbs Therapeutics’s 52-Week High Share Price?
Y-mAbs Therapeutics has traded as high as $20.90 over the past 52 weeks -
What Is Y-mAbs Therapeutics’s 52-Week Low Share Price?
Y-mAbs Therapeutics has traded as low as $6.09 over the past 52 weeks
Y-mAbs Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Y-mAbs Therapeutics?
-
How Much Debt Does Y-mAbs Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Y-mAbs Therapeutics Have?
Cash and short term investments quarterly total is $68.1M -
What Is Y-mAbs Therapeutics’s Book Value Per Share?
Book value per share is 2.06
Is Y-mAbs Therapeutics Cash Flow Positive?
-
What Is YMAB Cash Flow From Operations?
Cash flow from operations (TTM) is -$21.9M -
What Is Y-mAbs Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $3.4M -
What Is Y-mAbs Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $0
Y-mAbs Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
YMAB return on invested capital is -24.45% -
What Is Y-mAbs Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -18.5% -
What Is YMAB Return On Equity?
ROE is a measure of profitability and is -24.45%
Y-mAbs Therapeutics Earnings Date & Stock Price
-
What Is Y-mAbs Therapeutics's Stock Price Today?
A single share of YMAB can be purchased today for 10.01 -
What Is Y-mAbs Therapeutics’s Stock Symbol?
Y-mAbs Therapeutics trades on the nasdaq under the ticker symbol: YMAB -
When Is Y-mAbs Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Y-mAbs Therapeutics is scheduled on February 28, 2025 -
When Is YMAB's next ex-dividend date?
Y-mAbs Therapeutics's next ex-dividend date is December 12, 2024 -
How To Buy Y-mAbs Therapeutics Stock?
You can buy Y-mAbs Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Y-mAbs Therapeutics Competitors
-
Who Are Y-mAbs Therapeutics's Competitors?
Below is a list of companies who compete with Y-mAbs Therapeutics or are related in some way:
Y-mAbs Therapeutics Dividend Yield
-
What Is YMAB Dividend Yield?
Y-mAbs Therapeutics’s dividend yield currently is 0% -
What Is Y-mAbs Therapeutics’s Payout Ratio?
Y-mAbs Therapeutics’s payout ratio is 0% -
When Did Y-mAbs Therapeutics Last Pay A Dividend?
The latest dividend pay date is December 12, 2024 -
What Is Y-mAbs Therapeutics’s Dividend Per Share?
Y-mAbs Therapeutics pays a dividend of $0.00 per share
Y-mAbs Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -8.74% |
| Revenue: | -9.74% | -20.64% |
Analyst Recommendations
| Buy Recommendations: | 7 |
|---|---|
| Hold Recommendations: | 1 |
| Sell Recommendations: | 1 |
| Price Target: | 20.64 |
| Upside from Last Price: | 106.16% |